Your browser is no longer supported. Please, upgrade your browser.
NEW! Auto Refresh is now available in Screener. Let us know what you think. ×
SNY Sanofi daily Stock Chart
Index- P/E23.61 EPS (ttm)2.09 Insider Own- Shs Outstand2.61B Perf Week0.30%
Market Cap128.90B Forward P/E15.15 EPS next Y3.26 Insider Trans- Shs Float2.37B Perf Month-1.77%
Income5.51B PEG2.78 EPS next Q0.92 Inst Own10.50% Short Float0.08% Perf Quarter-7.50%
Sales41.32B P/S3.12 EPS this Y18.60% Inst Trans1.46% Short Ratio1.34 Perf Half Y-2.14%
Book/sh24.37 P/B2.02 EPS next Y2.10% ROA5.10% Target Price59.57 Perf Year-2.76%
Cash/sh2.02 P/C24.39 EPS next 5Y8.50% ROE8.80% 52W Range42.16 - 54.98 Perf YTD11.78%
Dividend1.61 P/FCF- EPS past 5Y-3.90% ROI7.00% 52W High-10.26% Beta1.07
Dividend %3.26% Quick Ratio1.40 Sales past 5Y1.80% Gross Margin68.00% 52W Low17.02% ATR0.98
Employees113496 Current Ratio1.40 Sales Q/Q16.10% Oper. Margin20.60% RSI (14)50.94 Volatility1.22% 1.67%
OptionableYes Debt/Eq0.26 EPS Q/Q69.70% Profit Margin13.20% Rel Volume0.71 Prev Close48.75
ShortableYes LT Debt/Eq0.19 EarningsOct 29 BMO Payout43.10% Avg Volume1.37M Price49.34
Recom1.70 SMA201.57% SMA50-1.69% SMA2000.73% Volume976,666 Change1.21%
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Aug-28-09Upgrade JP Morgan Neutral → Overweight
Jun-29-09Downgrade JP Morgan Overweight → Neutral
May-28-09Upgrade Citigroup Hold → Buy
Apr-30-09Upgrade JP Morgan Neutral → Overweight
Mar-23-09Upgrade Jefferies & Co Underperform → Hold
Mar-17-09Initiated Credit Suisse Outperform
Feb-19-09Upgrade JP Morgan Underweight → Neutral
Jan-26-09Initiated Jefferies & Co Underperform
Nov-07-08Downgrade UBS Neutral → Sell
Sep-23-08Downgrade Credit Suisse Neutral → Underperform
Oct-24-07Initiated Bernstein Mkt Perform
Sep-06-07Initiated UBS Neutral
Jul-18-07Upgrade HSBC Securities Neutral → Overweight
Jun-14-07Reiterated Banc of America Sec Buy $50 → $48
Oct-12-15 04:31PM  Indexes Close Up Across The Board; Facebook Gains, But Twitter Falls at Investor's Business Daily
Oct-09-15 02:00PM  Alnylam Initiates Extension Study on ALN-AT3 for Hemophilia
Oct-08-15 10:13AM  The FDA Approved Mercks Drug Keytruda for Lung Cancer Treatment
09:30AM  Sanofi Unveils New Positive Data on Lemtrada and Aubagio
07:54AM  Early movers: COST, DPZ, CC, SHAK, EMC, BMR & more at CNBC
07:25AM  Genzyme is not calling its newest MS drug a 'cure', but it looks like one in most patients at
01:00AM  Treatment Effects Maintained Over Five Years in Majority of Patients with Relapsing Remitting Multiple Sclerosis who Received Genzymes Lemtrada® (alemtuzumab) in Clinical Trials Business Wire
Oct-07-15 12:02PM  Cholesterol Busters Will Be Cheaper but Remain Top Sellers at Motley Fool
05:11AM  Drugmaker Sanofi trying to get French workers to work longer hours AFP
03:00AM  New Analysis Suggests Aubagio® (teriflunomide) Slows Brain Atrophy in People with Relapsing Multiple Sclerosis Business Wire
Oct-06-15 05:10PM  Express Scripts Says It Will Save America Money On New Cholesterol Drugs, But Its Math Doesn't Check Out at Forbes
09:40AM  Eli Lilly Traded above Its 100-Day Moving Average
07:05AM  Another Month, Another Crushing Decline for MannKind at Motley Fool
Oct-05-15 02:12PM  Falling Energy Prices Subdue the Eurozones September Inflation
12:53PM  MannKind Silent on Debt Conversion, Suggesting Costly Cash Settlement at TheStreet
09:00AM  Genzyme Introduces vs.MS, a Global Initiative Aimed at Uncovering the Often Unspoken Challenges of MS to Drive Better Informed Care Business Wire
Oct-02-15 04:15PM  Sanofi Opts into Alnylam's ALN-AT3 Hemophilia Program
Oct-01-15 01:35PM  MannKind Cuts Its Headcount, But Will It Matter? at Motley Fool
08:55AM  Sanofi Announces Launch of Authorized Generic Version of Arava® (Leflunomide) Tablets PR Newswire
07:00AM  Alnylam and Genzyme Announce that Genzyme Opts into ALN-AT3 Hemophilia Program for Development and Commercialization Outside of North America and Western Europe Business Wire
Sep-30-15 06:06PM  Sanofis Profitability Improved in 2Q15
06:06PM  How Did Merial Contribute to Sanofis 2Q15 Growth?
05:38PM  Why Novo Nordisk Is All in on New Diabetes Drug at TheStreet
05:06PM  How Did Sanofi Pasteur Perform in 2Q15?
04:06PM  Other Sanofi Franchises that Drove Pharmaceutical Growth in 2Q15
Sep-29-15 04:55PM  Sanofi, Eli Lilly Agree to Settle Lantus Patent Litigation
04:35PM  Alnylam's Extension Study on Patisiran Reveals Positive Data
04:07PM  Vanguard European Stock Index Fund Investor Shares (VEURX)
03:11PM  Diabetic Investor On MannKind: 'There's A Reason Why So Many People Are Short This Stock'
10:05AM  Bristol-Myers Squibbs Cardiovascular Segment in 2Q15
09:10AM  Regeneron Pharmaceuticals and Sanofi Grab Another Important Win at Motley Fool
08:00AM  Sanofi New Drug Application for Lixisenatide Accepted for Review by FDA PR Newswire
Sep-28-15 04:47PM  Eli Lilly (LLY) Stock Closed Down After Settlement with Sanofi at TheStreet
04:35PM  Regeneron/Sanofi's PCSK9 Inhibitor Praluent Approved in EU
04:17PM  Despite EU OK, Regeneron Crumbles Below 200-Day
03:09PM  Sanofi settles lawsuit enabling rival to Lantus insulin
01:39PM  Sanofi, Eli Lilly reach deal on insulin product
01:06PM  Was 2Q15 Good for Sanofis Established Rx Products?
11:58AM  This is What Hedge Funds Have to Say about Two Healthcare Stocks on the Move at Insider Monkey
09:47AM  Sanofi says reaches patent deal with Eli Lilly on Lantus SoloSTAR
09:33AM  Sanofi Reaches Patent Settlement on Lantus® SoloSTAR® PR Newswire
01:00AM  Regeneron and Sanofi Announce Approval of Praluent® (alirocumab) for the Treatment of Hypercholesterolemia in the European Union PR Newswire
Sep-25-15 11:59AM  The Price War for New Cholesterol Drugs Is Heating Up at Motley Fool
Sep-24-15 07:00PM  Sanofi Said to Consider Sale of Bio-Surgery, Renal Businesses at Bloomberg
Sep-23-15 03:06PM  Did Genzyme Drive Sanofis Growth in 2Q15?
03:06PM  How Pricing Affected Sanofis Diabetes Franchise in 2Q15
07:00AM  More Than 50 Presentations of New Data from Genzymes Multiple Sclerosis Franchise to be Featured at ECTRIMS Business Wire
Sep-21-15 04:36PM  What Drove Sanofis Growth in 2Q15?
04:35PM  What Was the Market Response to Sanofis 2Q15 Earnings?
11:06AM  Regeneron Has Long Pipeline Products
Sep-18-15 09:08AM  Regeneron and Shire Drag Down Top Ten Stocks by Market Cap
Sep-17-15 11:00PM  The world could run out of one of the most effective snake bite medicines by 2016
06:22PM  Regeneron and Endo International Underperform
06:02PM  Novo Nordisk's Victoza Fares Better than Sanofi's Lyxumia
07:57AM  Amgen's Acquisition Of Dezima And CETP Drug Like Pfizer's '03 Buy Of Esperion. Will History Repeat? at Forbes
Sep-16-15 05:05PM  Alnylam Reports Positive Initial Phase I Data on ALN-AS1
11:40AM  Chardan's Amusa Is Downgrading Amicus Therapeutics: Here's Why
Sep-14-15 04:00PM  Sanofi's (SNY) LixiLan Positive in Phase III Diabetes Study
08:00AM  Sanofi Reports Positive Top-Line Results in Second Pivotal LixiLan Phase III Study PR Newswire
Sep-11-15 06:00PM  Cramer: Signals from short sellers
07:42AM  Why MannKind Corporation Fell 11% in August at Motley Fool
07:00AM  Eli Lilly expands size of new Kendall Square innovation center at
Sep-10-15 11:45AM  Enrollment balloons in WPIs new drug manufacturing program at
Sep-09-15 03:49PM  New Class of Cholesterol Drugs Should Cost Much Less, Report Says at The Wall Street Journal
12:17PM  MannKind: Failure to Launch at
11:47AM  Piper Jaffray Drops Hammer On MannKind
Sep-08-15 06:52PM  New Class of Cholesterol Drugs Should Cost Much Less, Report Says at The Wall Street Journal
11:59AM  Amgen, Regeneron Upgraded On Cholesterol Drug Promise at Investor's Business Daily
07:39AM  Investment in Watertowns Selecta hints at growing interest from Genzyme, Sanofi at
06:13AM  Top 10 Hottest Stocks on Social Media This Week at TheStreet
Sep-07-15 11:16AM  Doctors Without Borders: snakebite treatment running out
Sep-05-15 06:18AM  3 Stocks to Avoid This Fall at Motley Fool
Sep-04-15 11:14AM  PCSK9 Drugs Are Here (and Way Over There) at Motley Fool
07:10AM  5 things to start the day: Tampas investment hot spot and St. Petes Good Burgers award winners at
Sep-03-15 08:03PM  UPDATE 2-Sanofi's Genzyme pays $32.59 mln in criminal Seprafilm case Reuters
07:57PM  Sanofi's Genzyme pays $32.59 million in criminal Seprafilm case Reuters
02:15PM  After Biogen deal, Florida biotech opening Cambridge office at
Sep-02-15 04:45PM  Regeneron and Sanofi Present Encouraging Praluent Data
09:22AM  Amgen's Next-Generation Cholesterol Drug Is Approved, but Pricing Is a Huge Concern at Motley Fool
Sep-01-15 04:45PM  Sanofi Teams Up with Google Life Sciences for Diabetes
04:05PM  Joslin partnering with Google, Sanofi to help disrupt diabetes at
04:05PM  Google, Sanofi to Jointly Improve Diabetes Management
09:37AM  Sanofi Earnings Q2, 2015
09:32AM  Google Teams up with Sanofi on Diabetes Care
09:32AM  Google Teams up with Sanofi on Diabetes Care at Bloomberg
09:00AM  Regeneron and Sanofi Announce New Positive Praluent® (alirocumab) Phase 3 Data Presented at ESC Congress 2015 PR Newswire
Aug-31-15 07:55PM  How Google looks to change the management of diabetes at
05:31PM  Google's Life Sciences group is making another big move to treat diabetes Business Insider
02:09PM  Google wants to disrupt diabetes with new Sanofi partnership at Silicon Beat
01:46PM  5 Things MannKind Corporation's Management Team Wants You To Know at Motley Fool
10:26AM  Google, Sanofi team up to improve diabetes care Reuters
09:01AM  Sanofi to Collaborate with Google Life Sciences to Improve Diabetes Health Outcomes PR Newswire
09:00AM  Google Pairs With Sanofi to Move Diabetes Patients to Cloud at Bloomberg
09:00AM  Google, Sanofi Team Up on Diabetes Research at The Wall Street Journal
Aug-28-15 10:35AM  Amgen's PCSK9 Inhibitor, Repatha, Approved in the U.S.
08:37AM  Time to Buy Amgen After Newly Approved Drug? at TheStreet
Aug-27-15 06:49PM  Amgen's Repatha OK'd With Similar Label To Praluent at Investor's Business Daily
03:40PM  Oncolytics' Reolysin Phase II Lung Cancer Study Enrolled
02:31PM  Cholesterol drug wars
11:24AM  Germany Helps Eurozone Business Activity Rise in August Market Realist
Sanofi researches, develops, and markets various therapeutic solutions. Its products comprise diabetes solutions, including Lantus, Apidra, and Insuman that are human insulin analogs; Amaryl, an oral sulfonylurea; Lyxumia, a glucagon-like peptide-1 receptor agonist; and Afrezza, an inhaled insulin to improve glycemic control, as well as Toujeo, an insulin glargine. The company also offers Cerezyme to treat gaucher disease; Myozyme/Lumizyme for the pompe disease treatment; Fabrazyme for fabry disease treatment; and Aldurazyme to treat mucopolysaccharidosis type I, as well as provides Aubagio and Lemtrada for multiple sclerosis. In addition, it provides Jevtana for prostate cancer; Taxotere for the treatment of breast, non-small cell lung, prostate, gastric, and head and neck cancers; Thymoglobulin to treat acute rejection in organ transplantation, aplastic anemia, and graft-versus-host diseases; Eloxatin for colorectal cancer; Mozobil for treating hematologic malignancies; and Zaltrap for oxaliplatin resistant metastatic colorectal cancer. Further, the company offers other prescription drugs, such as Plavix for atherothrombosis and acute coronary syndrome; Lovenox for the treatment and prevention of deep vein thrombosis and acute coronary syndromes; Aprovel/CoAprovel for hypertension; Renagel/Renvela to treat chronic kidney disease; Depakine for epilepsy; Synvisc/Synvisc-One for the treatment of pain associated with osteoarthritis of the knee; Stilnox/Ambien/Myslee to treat sleep disorders; Multaq for atrial fibrillation; Allegra for the treatment of allergic rhinitis and urticarial; Actonel for osteoporosis and paget's disease; and Auvi-Q/Allerject for the treatment of severe allergic reactions. Additionally, it offers consumer health care products and generic medicines; and vaccine and animal health products. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerOct 06Buy472.3311,0405,214,51923,108,570Oct 08 05:50 PM
Sanofi10% OwnerOct 06Buy459.7180,53837,024,19723,097,530Oct 08 05:45 PM
Sanofi10% OwnerJul 27Buy537.4810,6395,718,27222,869,783Jul 29 05:46 PM
Sanofi10% OwnerDec 24Buy398.7930,00211,964,50122,859,144Dec 29 05:40 PM
Sanofi10% OwnerDec 23Buy392.23171,45767,251,14222,829,142Dec 29 05:40 PM
Sanofi10% OwnerOct 16Buy335.35122,12740,955,05722,657,685Oct 20 05:45 PM
Sanofi10% OwnerOct 15Buy328.16158,36851,970,26522,535,558Oct 17 05:05 PM